Last reviewed · How we verify
Recombinant FVIII
At a glance
| Generic name | Recombinant FVIII |
|---|---|
| Also known as | ADVATE |
| Sponsor | Fondazione Angelo Bianchi Bonomi |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
- Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs (PHASE2, PHASE3)
- Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
- Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patients With Severe Hemophilia A in India
- A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
- SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (PHASE3)
- Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A (PHASE1)
- Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |